|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The meta-analysis included 58 eligible studies demonstrated that harboring <i>XPA</i> rs10817938, <i>XPD</i> rs238406 increased overall cancer risk, however, <i>XPA</i> rs2808668 SNP in overall cancer analysis and <i>XPF</i> rs3136038 in the digestive system remarkably reduced the cancer risk.
|
31333776 |
2019 |
|
Lymphopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Univariate statistical analyses revealed that patients with <i>ERCC2</i> rs13181 T/G and/or <i>CYP3A4</i> rs2740574 A/G genotypes are more likely to develop alopecia; patients with <i>ERCC2</i> rs238406 C/C genotype may develop leukopenia, and patients with <i>GSTT1</i>-null genotype could develop lymphocytopenia (III-IV).
|
30914949 |
2019 |
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The meta-analysis included 58 eligible studies demonstrated that harboring <i>XPA</i> rs10817938, <i>XPD</i> rs238406 increased overall cancer risk, however, <i>XPA</i> rs2808668 SNP in overall cancer analysis and <i>XPF</i> rs3136038 in the digestive system remarkably reduced the cancer risk.
|
31333776 |
2019 |
|
Alopecia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Univariate statistical analyses revealed that patients with <i>ERCC2</i> rs13181 T/G and/or <i>CYP3A4</i> rs2740574 A/G genotypes are more likely to develop alopecia; patients with <i>ERCC2</i> rs238406 C/C genotype may develop leukopenia, and patients with <i>GSTT1</i>-null genotype could develop lymphocytopenia (III-IV).
|
30914949 |
2019 |
|
Childhood Neuroblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here we endeavored to determine the relevance of <i>XPD</i> gene polymorphisms and neuroblastoma susceptibility in Chinese children genotyping three <i>XPD</i> polymorphisms (rs3810366, rs13181 and rs238406) in 505 cases and 1070 controls and assessing their contributions to neuroblastoma risk.
|
30089098 |
2018 |
|
Central neuroblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here we endeavored to determine the relevance of <i>XPD</i> gene polymorphisms and neuroblastoma susceptibility in Chinese children genotyping three <i>XPD</i> polymorphisms (rs3810366, rs13181 and rs238406) in 505 cases and 1070 controls and assessing their contributions to neuroblastoma risk.
|
30089098 |
2018 |
|
Neuroblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here we endeavored to determine the relevance of <i>XPD</i> gene polymorphisms and neuroblastoma susceptibility in Chinese children genotyping three <i>XPD</i> polymorphisms (rs3810366, rs13181 and rs238406) in 505 cases and 1070 controls and assessing their contributions to neuroblastoma risk.
|
30089098 |
2018 |
|
Prostate carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a hospital-based case-control study of 1,004 PCa cases and 1,055 cancer-free controls, we genotyped eight potentially functional single nucleotide polymorphisms (SNPs) of NER genes (i.e., XPC, rs2228001 T>G and rs1870134 G>C; XPD, rs13181 T>G and rs238406 G>T; XPG, rs1047768 T>C, rs751402 C>T, and rs17655 G>C; and XPF, rs2276464 G>C) and assessed their associations with risk of PCa by using logistic regression analysis.
|
27974699 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
|
0.010 |
GeneticVariation
|
BEFREE |
The R156R (C to A, rs238406) polymorphism of ERCC2 gene was investigated by the PCR-RFLP technique in 400 patients with ovarian carcinoma and 400 age- and sex matched non-cancer controls.
|
27888704 |
2017 |
|
Malignant neoplasm of ovary
|
|
0.010 |
GeneticVariation
|
BEFREE |
The R156R (C to A, rs238406) polymorphism of ERCC2 gene was investigated by the PCR-RFLP technique in 400 patients with ovarian carcinoma and 400 age- and sex matched non-cancer controls.
|
27888704 |
2017 |
|
Ovarian Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The R156R (C to A, rs238406) polymorphism of ERCC2 gene was investigated by the PCR-RFLP technique in 400 patients with ovarian carcinoma and 400 age- and sex matched non-cancer controls.
|
27888704 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a hospital-based case-control study of 1,004 PCa cases and 1,055 cancer-free controls, we genotyped eight potentially functional single nucleotide polymorphisms (SNPs) of NER genes (i.e., XPC, rs2228001 T>G and rs1870134 G>C; XPD, rs13181 T>G and rs238406 G>T; XPG, rs1047768 T>C, rs751402 C>T, and rs17655 G>C; and XPF, rs2276464 G>C) and assessed their associations with risk of PCa by using logistic regression analysis.
|
27974699 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
|
0.010 |
GeneticVariation
|
BEFREE |
ERCC2 rs238406 showed a marginally significant association with EGFR mutant lung adenocarcinoma in the validation stage (P=0.096).
|
29173771 |
2017 |
|
Squamous cell carcinoma of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that ERCC5/XPG rs2094258 and rs873601 and ERCC2/XPD rs238406 SNPs were independently associated with poorer DFS and OS of ESCC patients [ERCC5/XPG rs2094258: CT+TT vs. CC: adjusted hazards ratio (adjHR) = 1.68 and P = 0.012 for DFS; adjHR = 1.99 and P = 0.0001 for OS; ERCC5/XPG rs873601: GA+GG vs. AA: adjHR = 1.59 and P = 0.024 for DFS; adjHR = 1.91 and P = 0.0005 for OS; ERCC2/XPD rs238406: TT vs. GG+GT: adjHR = 1.43 and P = 0.020 for DFS; adjHR = 1.52 and P = 0.008 for OS].
|
27246611 |
2016 |
|
Brain Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the present work, we carried out a comprehensive meta-analysis of results from all published data (5 data sets for rs11615, 7 for rs3212986, 11 for rs13181, 5 for rs1799793, 3 for rs238406, and 4 for rs17655) to evaluate risk of brain tumors contributed by the polymorphisms being investigated.
|
26264164 |
2016 |
|
Malignant neoplasm of endometrium
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of the study was to determine the relationship between gene polymorphism R156R (C to A, rs238406) of ERCC2 gene and modulation of the risk of endometrial cancer in Poland.
|
26349749 |
2016 |
|
Endometrial Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The aim of the study was to determine the relationship between gene polymorphism R156R (C to A, rs238406) of ERCC2 gene and modulation of the risk of endometrial cancer in Poland.
|
26349749 |
2016 |
|
Malignant neoplasm of stomach
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer.
|
26782397 |
2015 |
|
Stomach Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer.
|
26782397 |
2015 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To validate genetic biomarkers of the disease, we explored the effects of the two synonymous polymorphisms [Pro206Pro (rs915927) and Arg156Arg (rs238406)] in the DNA repair genes XRCC1 and ERCC2 at chromosome 19q13.2-3 on breast cancer susceptibility among nonsmoking Chinese.
|
22579466 |
2012 |
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
To validate genetic biomarkers of the disease, we explored the effects of the two synonymous polymorphisms [Pro206Pro (rs915927) and Arg156Arg (rs238406)] in the DNA repair genes XRCC1 and ERCC2 at chromosome 19q13.2-3 on breast cancer susceptibility among nonsmoking Chinese.
|
22579466 |
2012 |
|
Xeroderma Pigmentosum, Complementation Group D
|
|
0.010 |
GeneticVariation
|
BEFREE |
The variant homozygotes of XPD p.Arg(156)Arg (rs238406) polymorphism were associated with a significantly increased risk of grade 3 or 4 hematologic toxicity (adjusted odds ratios, 3.24; 95% confidence interval, 1.35-7.78; P for trend = 0.009), and, more specifically, severe leukopenia toxicity (P for trend = 0.005).
|
19458053 |
2009 |
|
Leukopenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The variant homozygotes of XPD p.Arg(156)Arg (rs238406) polymorphism were associated with a significantly increased risk of grade 3 or 4 hematologic toxicity (adjusted odds ratios, 3.24; 95% confidence interval, 1.35-7.78; P for trend = 0.009), and, more specifically, severe leukopenia toxicity (P for trend = 0.005).
|
19458053 |
2009 |